Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
WHO prequalifies first generic hepatitis C medicine and first HIV self-test

WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories Ltd., India.

Published
3 hours ago
From
World Health Organization
More people living with HIV in Kyiv accessing antiretroviral therapy

A public–private partnership between the Elena Pinchuk ANTIAIDS Foundation and the city of Kyiv.

Published
14 July 2017
From
UNAIDS
An arbitrary benchmark for access to new drugs

Policy is an admission the UK cannot afford to be at the cutting edge.

Published
11 July 2017
From
Financial Times
Senior MPs urge post-Brexit EU drug regulation deal

The move would be "in the interests of public health and safety," say Greg Clark and Jeremy Hunt.

Published
04 July 2017
From
BBC Health
MSF: HIV response in West and Central Africa will not succeed if key barriers remain unaddressed

MSF strongly commends the vital leadership shown by UNAIDS and African states in initiating the Acceleration Plan. African leaders are urged to address any limiting factors which may prevent its full realisation. These include legal and policy blockages, centralised health systems, weak procurement and supply chain management, financial barriers, including user fees for patients, and high levels of stigma. MSF also asks for the Acceleration Plan to soon include remaining countries in the region that face similar treatment gaps.

Published
04 July 2017
From
Médecins Sans Frontières (MSF) International
Kenya to introduce better treatment for people living with HIV

To accelerate access to better antiretroviral (ARV) drugs, the Government of Kenya and Unitaid today announced the introduction of dolutegravir, a new first-line drug for people living with HIV, making Kenya the first African country to introduce the generic version of this new drug for routine use.

Published
28 June 2017
From
UNITAID
Dolutegavir access in the Asia-Pacific region

This factsheet provides information on the use of dolutegravir in HIV treatment and access to dolutegravir under Medicines Patent Pool voluntaray licenses.

Published
27 June 2017
From
amfAR Treat Asia
FDA Approves Generic Truvada for HIV Treatment and PrEP

In a move that has taken HIV advocates by surprise and stewed considerable confusion, the U.S. Food and Drug Administration (FDA) has approved a generic formulation of Gilead Sciences’ blockbuster antiretroviral (ARV) Truvada (tenofovir disoproxil fumarate/emtricitabine). This decision could have major implications for the future cost of Truvada, to insurers and consumers alike.

Published
10 June 2017
From
Poz
PrEP Stymied in Europe: What's the hold up?

Europe is the birthplace of the smallpox vaccine and the Renaissance, among other treasures. So why can’t this continent that has brought forth such cornerstones of public health and flourishing civilization deliver oral PrEP—a mere pill a day to prevent HIV, which already exists and is being successfully implemented in several countries, including Brazil, Kenya, South Africa and the US?

Published
08 June 2017
From
AVAC
On the front lines of Russia's 'staggering' HIV epidemic

According to the United Nations' UNAIDS program, Russia had the third-highest number of new HIV infections globally in 2015, behind South Africa and Nigeria.

Published
07 June 2017
From
CNN
← First12345...125Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.